Kyle William Robinson

Kyle William Robinson serves as Clinical Associate Professor of Medicine in the Department of Medicine at the University of Pennsylvania's Perelman School of Medicine. He maintains clinical practice at the Abramson Cancer Center with hospital privileges at the Hospital of the University of Pennsylvania. His dual expertise spans Hematology and Medical Oncology, focusing on complex malignancies including prostate cancer, lung cancer, and lymphoma.

His educational pathway includes:

• Medical Degree: Temple University School of Medicine
• Residency: Temple University Hospital
• Fellowship: Oregon Health & Science University

Dr. Robinson's research program targets critical gaps in cancer therapeutics through three interconnected domains. His prostate cancer work investigates germline variants and racial disparities using real-world cohorts, while lung cancer research examines immunotherapy optimization including late toxicities and biomarker-driven combinations. In hematology, he analyzes response kinetics for novel lymphoma therapies. This portfolio demonstrates translational rigor with direct clinical applicability.

Analysis of his 2021-2025 publications reveals consistent focus on evidence generation for precision oncology. Key themes include genetic epidemiology of prostate cancer, immunotherapy safety management in NSCLC, and biomarker-driven treatment sequencing. His work increasingly addresses health disparities and real-world implementation barriers alongside therapeutic innovation.

At the Abramson Cancer Center, Dr. Robinson leads a multidisciplinary team integrating medical oncology, genomics, and supportive care. His clinical practice directly informs research questions while trial participation provides patients access to cutting-edge therapies. This bidirectional translation characterizes his academic medicine approach.